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The lungs represent a complex immune setting, balancing external environmental signals
with a poised immune response that must protect from infection, mediate tissue repair,
and maintain lung function. Innate lymphoid cells (ILCs) play a central role in tissue
repair and homeostasis, and mediate protective immunity in a variety of mucosal tissues,
including the lung. All three ILC subsets are present in the airways of both mice and
humans; and ILC2s shown to have pivotal roles in asthma, airway hyper-responsiveness,
and parasitic worm infection. The involvement of ILC3s in respiratory diseases is less
well-defined, but they are known to be critical in homeostasis, infection and inflammation
at other mucosal barriers, such as the gut. Moreover, they are important players in the
IL17/IL22 axis, which is key to lung health. In this review, we discuss the emerging role of
ILC3s in the context of infectious and inflammatory lung diseases, with a focus on data
from human subjects.
Keywords: ILC3, lung disease, pnemonia, tuberulosis, COPD, airway hypersensitivity, pulmonary fibrosis
INTRODUCTION
The lungs are complex organs, the proper functioning of which is essential for good health,
but whose exposure to the external environment renders them susceptible to infections and
environmental toxins. The average person will breathe 11,500 L of air into their lungs in a given
day. This air is full of small particulate matter that includes more than just the bacteria and
viruses most typically associated with a lung immune response, and also includes dust, dirt, smoke,
pollen, aerosols, and liquid droplets. The lung immune environmentmust therefore strike a delicate
balance between dealing with this constant assault, whilst preventing immune mediated damage.
This results in an intricate immune setting that is still not completely understood (1), but which
growing evidence suggests includes an important role for innate lymphoid cells (ILCs).
Innate lymphoid cells (ILCs) are a family of innate immune cells that lack specific antigen
receptors but produce a broad range of effector cytokines and have diverse roles at barrier surfaces.
ILCs mediate protective immunity from pathogens and promote tissue repair and homeostasis
following infection, but may also play a role in pathogenesis when their functions become
dysregulated (2–4). Broadly, ILCs are classified into three subsets based on surface markers,
cytokine production, and transcription factor requirements (5). ILC1s are classically associated
with the immune response to viral infection and tumor cells, while ILC2s are often compared
to CD4+ Th2 cells and mediate the response to helminth infections and allergies. ILC3s are the
most heterogeneous subset of ILCs, defined by expression of the Retinoid-related orphan receptor
γt (RORγt), and produce IL-17, IL-22, granulocyte-macrophage colony stimulating factor (GM-
CSF) and/or tumor necrosis factor α (TNFα) in response to IL-23, IL1-β and aryl hydrocarbon
receptor (AHR) ligands (2, 6) (Figure 1). ILC3s can be broadly categorized into two lineages:
the lymphoid tissue inducer cells (LTi cells) including fetal and adult-equivalent LTi-like cells
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FIGURE 1 | Under conditions of stress or infection, ILC3s produce an array of effector cytokines in response to activating ligands secreted by phagocytic
mononuclear cells.
(7), that have established roles in lymphoid organogenesis and
secondary lymphoid tissue development, respectively; and non-
LTi ILC3s which may or may not express natural cytotoxicity
receptors Nkp44 and/or Nkp46 (8). ILC3s are widely distributed
throughout the body and are constitutively present at mucosal
barrier sites such as the lung, liver, gut, spleen, skin and secondary
lymphoid tissues (9), where they play crucial roles in immunity
and tissue homeostasis through the production of cytokines and
interaction with the adaptive immune system (10).
While all three ILC subsets have been identified in the
airways, the majority of studies to date have focused on ILC2s,
highlighting their importance in tissue repair, protection from
helminth infections, and involvement inmultiple allergic diseases
(3, 11, 12). However, ILC3s are in fact the most prevalent group
in human lung tissues (13), and their rapid secretion of IL-17A
and IL-22 has prompted investigations into their involvement in
inflammatory and infectious diseases in the lung, as the IL-17/IL-
22 axis is so important to lung health (14) (Overview in Figure 2).
Moreover, GM-CSF also plays an important role in allergic
airway disease, antimicrobial pulmonary host defense function,
and is essential for surfactant homeostasis (15). Although the
importance of ILCs as a source of GM-CSF in the lung remains
untested, ILC3s in the gut are known to orchestrate inflammation
through its activity (6).
INFECTIOUS DISEASES
The constitutive presence of ILC3s at mucosal barriers, including
the lung, and their rapid production of cytokines allows them
to efficiently orchestrate inflammation and antimicrobial peptide
production, providing essential protection at these mucosal sites
(4, 16, 17). Here we discuss several important human lung
infections in which ILC3s may play an important role.
Viral Infections
The influenza viruses are some of the most important
human respiratory pathogens, causing substantial seasonal, and
pandemic morbidity and mortality (18). Following infection,
the innate immune system provides the first line of defense,
with various innate cell types playing important roles in killing
infected cells and/or limiting viral replication. However, an
excessive innate immune response correlates with poor outcomes
and can lead to pathology (19, 20), and lung regeneration
following viral-induced injury is vital (18). ILC2s have been best
studied in relation to influenza, due to their ability to mediate
tissue repair following Influenza infection via the production of
amphiregulin (3). However, both IL-22 and IL-17 are implicated
in the immune response to pulmonary viral infection, suggesting
a potential role for ILC3s, particularly prior to the onset of the
adaptive immune response or in primary infection. Mice infected
with Influenza A/PR/8, for example, produced IL-17A as early
as 2 days post-infection, resulting in lung injury associated with
excessive neutrophil recruitment (21), and IL-17 deficiency or
treatment with anti-IL-17 antibodies is able to ameliorate IL-
17 associated lung injury in infected mice (22). However, as
with many things in immunology, this is a double edged sword,
as IL-17 also plays an important protective role in preventing
secondary bacterial infections. Two separate studies have shown
in co-infection experiments with influenza and Staphylococcus
aureus, that the induction of type I interferon from the virus
increased susceptibility to secondary bacterial pneumonia by
directly inhibiting IL-17 production (23, 24). Irrespective, IL-17
is likely to be relevant in human influenza infection, as elevated
levels of IL-17 and IL-17 associated cytokines are detected in
serum from humans infected with swine-origin Influenza virus
(22). As antigen-specific CD4+ T cells do not appear in the lung
earlier than 4 days post-infection (25), innate sources of IL-17 are
likely to play an important role. γδ T cells have been implicated
as being the early source of IL-17 (21, 26) however, although not
directly linked as yet, it is likely that ILC3s represent an additional
source of IL-17 during the first week of an influenza infection,
particularly in primary infections.
IL-22, also has critical functions in host defense and in
maintaining epithelial integrity during influenza infection (10,
27). In mice infected with a sub-lethal dose of H3N2 Influenza
A, ILCs had enhanced expression of IL-22 transcripts as early
as 2 days post-infection, and mice able to produce IL-22 had
reduced lung injury and better protection from post-influenza
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FIGURE 2 | Diverse and overlapping roles of IL-22 and IL-17 within the lung.
Streptococcus pneumoniae superinfection, in comparison to IL-
22-deficient animals (28). In another study, IL-22 knock out
mice were found to have exacerbated lung injury compared
with wild-type mice, correlating with decreased lung function
21 days post-infection with a PR8/34 H1N1 virus (29).
Similarly, Kumar et al. (30) found that IL-22−/− mice infected
with a PR8 Influenza virus had severely impaired epithelial
regeneration and continuous loss of body weight, which
was restored by adoptive transfer of IL-22 sufficient, “ILC3-
like” CD3−NCR1+NK1.1+ cells. Guo and Topham (31), also
identified a CD3-NCR1+NK1.1+ subset as the predominant
producers of IL-22, although the protective role of IL-22 was
less clear in this instance. Subsequently, transcription factor
staining and transcriptomics of mucosal barrier surfaces have
demonstrated that ILC3s are a major source of IL-22 (32).
Bacterial Pneumonia
Pneumonia remains one of the largest infectious causes of death
globally, accounting for the deaths of 16% of children under 5
years old (33).
The severity of pneumonia depends on the interplay between
the ability of the host to control infection and the extent to
which the stress of microbial challenge can be tolerated (34).
IL-17 is important in the control of several key bacterial causes
of pneumonia in humans, including Klebsiella pneumoniae,
Streptococcus pneumoniae, and Pseudomonas aeruginosa (23, 35–
37). Humans with inherited complete autosomal recessive IL-
17RA deficiency, for example, have increased susceptibility to
pneumonia (38). In mechanistic studies, IL-17R knockout mice
were found to be particularly susceptible to K. pneumonia,
demonstrating 100% mortality after just 48 h in comparison
to 40% mortality amongst controls (39). This was attributed
to a considerable delay in alveolar neutrophil recruitment via
IL-17. Similarly, IL-17R deficient mice, or mice with depleted
neutrophil populations had significantly diminished protection
from pneumococcal infection in the lung, and IL-17 is known
to enhance the phagocytic activity of neutrophils in vitro (40).
These observations are supported by recent work showing that
IL-17 signaling in the lung epithelium plays a critical role
in establishing the chemokine gradients that are essential for
mucosal immunity against pulmonary bacterial pathogens. Here,
mice that lacked IL-17R expression specifically on lung epithelia
lost CXCR5 signaling and failed to recruit sufficient neutrophils
to clear K. pneumoniae (36). The protective effect of IL-17
is not only limited to the activity neutrophils. Clearance of
primary infection with S. pneumoniae, for example, requires
the recruitment of monocyte/macrophages, and this protective
response is blocked by the depletion of IL-17 (41). Again, while
Th17 and γδ T-cells are important sources of IL-17 in the recall
response to bacterial infection (37, 42), in primary infections,
other sources, including ILC3s are likely to be crucial. This is
highlighted by the recent work of Xiong et al. (43) demonstrating
the importance of ILCs in primary infection with K. pneumoniae.
This study described a positive feedback loop in which TNF-
producing monocytes recruited to lungs drove an increase in IL-
17-secreting ILCs, which in turn enhanced monocyte-mediated
bacterial uptake and killing. Importantly, bacterial clearance
was similar in T-cell deficient and WT mice, but depletion of
ILC3s led to increased bacterial burden and mortality (43). In
experimental infection with P. aeruginosa, for which IL-17 is also
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essential, 90% of early IL-17 production appears to come from
ILC3 rather than CD3+ lineages, including γδ T-cells (35).
As with viral infection, IL-22 also plays key roles in host
response to bacterial pneumonia. In mice, IL-22 is detected
in lungs as early as 6 h post-infection, where it increases lung
epithelial cell proliferation and significantly augments killing
of K. pneumoniae in vitro by upregulating the expression of
lipocalin-2 (44). The early expression of IL-22 implicates an
innate source. Following on from this Van Maele et al. (32),
using Rag−/− and Rag−/−/Il2rg−/− mice, demonstrated IL-22
production by CCR6+ ILC3s during S. pneumoniae infection.
Interestingly, this ILC3 response could be boosted by exogenous
administration of the TLR ligand flagellin, and was sufficient to
control and protect from an otherwise lethal infection (32). This
raises the intriguing possibility that modulation of ILC3s may
represent a novel treatment modality for some lung infections.
The potential interplay between IL-22 and IL-17 in bacterial
pneumonia is highlighted by recent work showing that, whilst
IL-17 driven neutrophil recruitment maybe required for bacterial
clearance, infection with P. aeruginosa in the absence of IL-
22 is associated with pathogenesis and increased susceptibility
driven by an excessive neutrophil response (45). Finally, IL-
22 production by ILC3s was recently found to be vital in
neonates, being the primary source of this cytokine in both
mice and humans. In this study, recruitment of IL-22-producing
ILC3s to the lung, driven by commensal microbes in the gut,
was required for protection from S. pneumoniae infection (46).
This unexpected link between the gut microbiome and ILC3-
mediated immunity in the lung again raises the possibility of
manipulating ILC3s to improve lung health. It also demonstrates,
as with primary infection, that the importance of ILC3 produced
cytokines may vary depending on the context.
Tuberculosis
Tuberculosis (TB), despite typically being a fully treatable disease,
continues to contribute to more deaths worldwide each year than
any other infectious disease (47), pulmonary or otherwise. While
the immune response to TB is complex and not fully understood,
human and mouse models have progressively elucidated roles
for many different immune cells including alveolar macrophages,
epithelial cells, and CD4+ T cells (48, 49). Studies of ILCs
in this mix are extremely limited to date. However, ILCs are
activated and accumulate in the lungs and lymph nodes of
mice following intranasal vaccination with Mycobacterium bovis
Bacillus Calmette-Guérin (BCG) (50). Moreover, their roles in
lung tissue repair, hepatic granuloma formation (3, 51), and pro-
inflammatory cytokine production support their involvement.
Indeed, prior to the description of ILCs, Feng et al. (52) found
that Rag−/−γ c−/− mice, which lack T-cells and all ILC subsets,
had significantly poorer survival than T-cell deficient Rag2−/−
mice or WT controls, reflected in a more than 2-fold increase in
lung bacterial burden. Consistent with this, whilst Th1-associated
molecules, such as TNFα and IFNγ are crucial to mycobacterial
resistance (53–55), recent studies have extended this to include
IL-17 and IL-22. BCG-infected mice, for example, fail to develop
mature granulomas in the absence of IL-17 (56), and both IL-17
and IL-22 protect mice from the hypervirulent strainMtbHN878
(57, 58). Using cells sorted from human lung tissue explants,
ILC3s have recently been show to upregulate GM-CSF and IL-
22 transcripts when stimulated with Mtb ex vivo (48), and IL-
22-producing NK cells, now recognized as ILC3s, inhibit Mtb
growth by enhanced phagolysosomal fusion (59). Additionally,
humans with inherited bi-allelic RORC mutations, which lead
to compromised IL-17A/F mediated immunity, have markedly
increased susceptibility to mycobacterial disease (60).
One potential mechanism by which ILCs may contribute to
the immune response to TB infection is through the formation of
inducible bronchus-associate lymphoid tissue (iBALT). These are
tertiary lymphoid structures that develop following pulmonary
inflammation, at least in part through the IL-17/22 axis,
and which appear to orchestrate protective immune responses
(57, 61–63). Several independent studies have highlighted the
importance of iBALT formation in the immunopathology of TB.
Mice deficient in IL-17 had reduced B cell follicle formations
during early stages of Mtb challenge, while IL-22-deficient
mice had impaired follicle formation at an intermediate stage,
although neither of these deficiencies impacted the mouse’s
ability to control the infection. A lack of IL-23, which induces
cytokine production by ILC3s, led to both a sustained follicle
deficiency and increased bacterial growth (64). Separately, IL-
17, and not IFNγ, was found to be required for mucosal
vaccine-induced immunity againstMtb, and was associated with
the induction of organized iBALT structures in the lung (65).
Thus, early and/or sustained production of IL17/IL22 by ILC3s
may play and important role in iBALT formation during Mtb
infection. It is important to note, however, that iBALT formation
can be observed in neonatal RORγt KO mice (66), showing that
ILC3s are not absolutely required for this process.
AUTOIMMUNE DISEASE
ILC3s have been associated with several autoimmune diseases,
including inflammatory bowel disease, multiple sclerosis,
psoriatic arthritis, and ankylosing spondylitis, either by direct
evidence or by involvement of the IL17/IL22 axis (67–70). ILCs
are also implicated in numerous autoimmune diseases which
can have lung associated pathology, including systemic sclerosis,
systemic lupus erythromatosus, and the ANCA-associated
vasculitides, however, the relationship is most clearly worked out
in asthma, COPD, and pulmonary fibrosis.
Asthma and Airway Hyper-Reactivity
Asthma is a chronic respiratory disease characterized by airflow
obstruction, excessive inflammation and airway remodeling (71).
IL-17 appears to be an important cytokine driving this this
condition. IL-17 expressing cells, for example, are elevated in
both sputum and Bronchoalveolar lavage fluid (BALF) from
asthmatic patients, (72) and more recently, IL-17+ ILC3s in
particular were found to be increased in BALF from human
patients with severe asthma (73). Consistent with this, ILC3 gene
signatures are enriched in total RNA from patients with adult
onset asthma (74). Inmice, ILC3s facilitate obesity-linked asthma
via IL-17 production. Here, in both wild-type mice fed a high
fat diet, and mice that are obese due to a mutation in the leptin
gene, airway hyperresponsiveness was found to mediated by IL-
17+ ILC3s (73). Importantly, this was observed in T-cell deficient
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mice and was induced by adoptive transfer of ILC3s into mice
lacking all lymphoid cells. Subsequently, IL-17-producing ILC3s
were similarly implicated in allergic asthma. Here, IL-17+ ILC3s
and ILC2s were increased in mice fed a high fat diet following
house dust mite challenge, and this was ameliorated by antibody
depletion of ILCs using anti-CD90 (75).
IL-22 expression is associated with increased eosinophil
recruitment to lungs and airway hyper-responsiveness, and can
be detected in mice with ovalbumin induced allergic asthma (76),
and in serum from human patients (77). The major source of IL-
22 in mouse models is yet to be confirmed, as one study identified
the origin to be CD4+ T cells (78), while another study found
it was predominantly produced by lineage negative, CD90+,
Sca-1+ ILCs (79). However, in both studies, as well as others,
neutralization of IL-22 led to increased eosinophil infiltration
and allergic inflammation, while treatment with recombinant IL-
22 ameliorated this response (76–79). Here, the implication that
IL-17 is detrimental and IL-22 protective in these situations is
likely to be a simplistic one due to the cross talk between these
cytokines. Besnard et al. (77), for example found that IL-22 played
a protective role in the initial stages following antigen challenge,
but exacerbated inflammation in the later stages.
COPD
Chronic obstructive pulmonary disease (COPD) is largely caused
by smoking, and is associated with an aberrant inflammatory
lung environment (80), characterized by lung destruction and
increased neutrophilic infiltration (81). Consistent with their
roles in tissue immunity and homeostasis, recent studies have
identified roles for ILCs in COPD, particularly ILC1s (82).
However, ILC3s may also be involved, as IL-17 is recognized as a
key driver of neutrophilic inflammation in COPD (83). In mice,
cigarette smoke exposure leads to an increase of all ILC subsets in
BALF, particularly IFNγ+ and IL-17+ ILCs (84). In line with this,
human patients with COPD have higher sputum IL-17 than non-
smoking controls (85), and IL-17-, IL-22-, and IL-23-expressing
cells are increased in bronchial biopsies from COPD patients
(81). While direct mechanistic evidence linking ILC3s to COPD
is limited, one human study showed that a subset of ILC3s was
notably increased in lung tissue from COPD patients, and an
increase in IL-17 and IL-22 production by ILC3s (13). In separate
work, gene set enrichment analysis revealed LTi ILC3s and NK
genes are enriched in lymphocytes sorted from human lungs
tissues of patients with severe COPD (86).
Pulmonary Fibrosis
Pulmonary fibrosis occurs as a result of damage and scarring of
the lung parenchyma that can have numerous causes including,
environmental toxins, medication side effects, radiation therapy,
and autoimmune conditions. In fibrotic disease, chronic
inflammation and persistent extracellular matrix deposition can
lead to remodeling and progressive tissue destruction (87). This
remodeling and extracellular matrix deposition is largely driven
by connective tissue cells, such as fibroblasts, whose functions are
directly affected by pro-fibrotic cytokines produced by adaptive
and innate immune cells (88). The types of inflammatory
processes facilitated by ILCs, and their cytokine expression
suggests they are substantial contributors to fibrosis (87). While
all three ILC subsets secrete fibroblast activating cytokines, ILC3s
have capacity to regulate synovial fibroblasts and connective
lung tissue cells via IL-17 (89, 90), and elevated levels of IL-
17 have been observed in patients with cystic and pulmonary
fibrosis (91, 92). In a mouse model of fibrosis, IL-17 was
produced early on (between days 2 and 7), and associated
with neutrophil influx into the lungs. Mice deficient in IL-17
had lower neutrophil frequencies and better disease outcomes
(92). It seems that timing is important, however, as treatment
with IL-17 has no effect on collagen deposition during chronic
disease (93).
IL-22 is also involved in fibrosis, again in a largely protective
role. In a mouse model of hypersensitivity pneumonia, for
example, blockade of IL-22 signaling caused accelerated lung
fibrosis and enhanced collagen deposition in the lung, which
was inhibited by the administration of recombinant IL-22
(94). Similarly, bleomycin treatment in mice, which induces
fibrosis, significantly reduced IL-22 in their lungs, and human
epithelial cell lines treated with IL-22 had a slower progression
to fibrosis (95). However, again this protective view of IL-
22 is probably simplistic as one study found that bleomycin
induced IL-22 production was only protective in IL-17 deficient
mice (96). Conversely, in the presence of IL-17, IL-22 was
proinflammatory and promoted airway pathology, which was
blocked by the administration of anti-IL-22 antibody. Clearly
then, the involvement of IL-17 and IL-22 in the lung should not
be considered separately. As important innate sources of both
cytokines in the lung, it appears likely that ILC3s would have a
role in pulmonary fibrosis and they produce represent promising
new targets for molecular therapies (92, 94).
CONCLUDING REMARKS
As we have highlighted here, there are many studies showing
the importance of ILC3 cytokines in lung immunity. In many
cases the early source of cytokines such as IL-17 and IL-22 has
been assumed to be γδ T cells, as antigen-specific T cells only
accumulate after several days (25). However, we now know that
ILC3s, though fewer in number, are prolific producers of IL-17
and/or IL-22, as well as other important lung cytokines such as
GM-CSF, and thus have the capacity to drive inflammation or
repair in a number of infectious and autoimmune diseases (97–
100). This is certainly supported by the relatively few studies to
date that have directly sought to investigate their importance as a
source of these cytokines. Clearly much remains to be done, but
the possibility that lung ILC3s may be manipulated to influence
lung health is intriguing and should encourage these further
studies.
AUTHOR CONTRIBUTIONS
AA and JP: Literature research and writing; HK and AL:
Literature research and editing.
FUNDING
This work was supported by Wellcome Trust by AL Grant No.
210662/Z/18/Z; HK Grant No. 202485/Z/16/Z.
Frontiers in Immunology | www.frontiersin.org 5 January 2019 | Volume 10 | Article 92
Ardain et al. ILC3s and Lung Disease
REFERENCES
1. Saluzzo S, Gorki AD, Rana BMJ, Martins R, Scanlon S, Starkl P,
et al. First-breath-induced type 2 pathways shape the lung immune
environment. Cell Rep. (2017) 18:1893–905. doi: 10.1016/j.celrep.2017.
01.071
2. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, et al.
Innate lymphoid cells drive IL-23 dependent innate intestinal pathology.
Nature (2010) 464:1371–5. doi: 10.1038/nature08949
3. Monticelli La, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK,
Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis
after infection with influenza virus. Nat Immunol. (2011) 12:1045–54.
doi: 10.1038/ni.2131
4. Satoh-Takayama N, Vosshenrich CAJ, Lesjean-Pottier S, Sawa S, Lochner M,
Rattis F, et al. Microbial flora drives interleukin 22 production in intestinal
NKp46+ cells that provide innate mucosal immune defense. Immunity
(2008) 29:958–70. doi: 10.1016/j.immuni.2008.11.001
5. Spits H, Artis D, ColonnaM, Diefenbach A, Di Santo JP, Eberl G, et al. Innate
lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol.
(2013) 13:145–49. doi: 10.1038/nri3365
6. Pearson C, Thornton EE, McKenzie B, Schaupp AL, Huskens N, Griseri T,
et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal
inflammation. eLife (2016) 5:1–21. doi: 10.7554/eLife.10066
7. Kim MY, Rossi S, Withers D, McConnell F, Toellner KM, Gaspal F,
et al. Heterogeneity of lymphoid tissue inducer cell populations present in
embryonic and adult mouse lymphoid tissues. Immunology (2008) 124:166–
74. doi: 10.1111/j.1365-2567.2007.02750.x
8. Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s):
origin, differentiation, and plasticity in humans and mice. Eur J Immunol.
(2015) 45:2171–82. doi: 10.1002/eji.201545598
9. Kim CH, Hashimoto-hill S, Kim M. Migration and tissue tropism
of innate lymphoid cells. Trends Immunol. (2016) 37:68–79.
doi: 10.1016/j.it.2015.11.003
10. Sonnenberg GF, Fouser La, Artis D. Border patrol: regulation of immunity,
inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat
Immunol. (2011) 12:383–90. doi: 10.1038/ni.2025
11. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank
JP, et al. Innate IL-13-producing nuocytes arise during allergic lung
inflammation and contribute to airways hyperreactivity. J Allergy
Clin Immunol. (2012) 129:191–8.e1–4. doi: 10.1016/j.jaci.2011.
09.041
12. Turner J-E, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld J-
C, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes
damage control in helminth-induced lung inflammation. J Exp Med. (2013)
210:2951–65. doi: 10.1084/jem.20130071
13. De Grove KC, Provoost S, Verhamme FM, Bracke KR, Joos GF, Maes T,
et al. Characterization and quantification of innate lymphoid cell subsets
in human lung. PLoS ONE (2016) 11:e0145961. doi: 10.1371/journal.pone.
0145961
14. Gurczynski SJ, Moore BB. IL-17 in the lung: the good, the bad, and the ugly.
Am J Physiol.(2017) 314:L6–16. doi: 10.1152/ajplung.00344.2017
15. Rösler B, Herold S. Lung epithelial GM-CSF improves host defense
function and epithelial repair in influenza virus pneumonia—a new
therapeutic strategy?Mol Cell Pediatr. (2016) 3:29. doi: 10.1186/s40348-016-
0055-5
16. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JKM, et al.
A human natural killer cell subset provides an innate source of IL-22 for
mucosal immunity. Nature (2009) 457:722–5. doi: 10.1038/nature07537
17. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, et al.
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing
precursors to RORC+CD127+ natural killer-like cells.Nat Immunol. (2009)
10:66–74. doi: 10.1038/ni.1668
18. Herold S, Becker C, Ridge KM, Budinger GRS. Influenza virus-induced lung
injury: pathogenesis and implications for treatment. Eur Respir J. (2015)
45:1463–78. doi: 10.1183/09031936.00186214
19. Cole SL, Ho L-P. Contribution of innate immune cells to pathogenesis
of severe influenza virus infection. Clin Sci. (2017) 131:269–83.
doi: 10.1042/CS20160484
20. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, et al. Early hypercytokinemia
is associated with interferon- induced transmembrane protein-3 dysfunction
and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA. (2014)
111:769–74. doi: 10.1073/pnas.1321748111
21. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, Enelow RI, et al.
Critical role of IL-17RA in immunopathology of inflenza infection. J
Immunol. (2013) 183:5301–10. doi: 10.4049/jimmunol.0900995.
22. Li C, Yang P, Sun Y, Li T, Wang C, Wang Z, et al. IL-17 response mediates
acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus.
Cell Res. (2011) 22:528–38. doi: 10.1038/cr.2011.165
23. Kudva A, Scheller EV, Robinson KM, Crowe CR, Mi Choi S, Slight
SR, et al. Influenza A inhibits Th17-mediated host defense against
bacterial pneumonia in mice. J Immunol. (2011) 186:166–1674.
doi: 10.1021/nl061786n.Core-Shell
24. Robinson KM, Choi SM, McHugh KJ, Mandalapu S, Enelow RI, Kolls
JK, et al. Influenza A exacerbates Staphylococcus aureus pneumonia by
attenuating IL-1 production in mice. J Immunol. (2013) 191:5153–9.
doi: 10.4049/jimmunol.1301237
25. Doherty PC, Christensen JP. ACCESSING COMPLEXITY : the dynamics
of virus-specific T cell Responses. Annu Rev Immunol. (2000) 18:561–92.
doi: 10.1146/annurev.immunol.18.1.561
26. Xue C, Wen M, Bao L, Li H, Li F, Liu M, et al. Vγ4+ γδT Cells
Aggravate severe H1N1 inuenza virus infection-induced acute pulmonary
immunopathological injury via secreting interleukin-17A. Front. Immunol.
(2017) 8:1054. doi: 10.3389/?mmu.2017.01054
27. Rutz S. IL-22, not simply a Th17 cytokine. Immunol Rev. (2013) 252:116–32.
doi: 10.1111/imr.12027
28. Ivanov S, Renneson J, Fontaine J, BarthelemyA, Paget C, Fernandez EM, et al.
Interleukin-22 reduces lung inflammation during influenza A virus infection
and protects against secondary bacterial infection. J Virol. (2013) 87:6911–24.
doi: 10.1128/JVI.02943-12
29. Pociask DA, Scheller EV, Mandalapu S, McHugh KJ, Enelow RI, Fattman CL,
et al. IL-22 is essential for lung epithelial repair following influenza infection.
Am J Pathol. (2013) 182:1286–96. doi: 10.1016/j.ajpath.2012.12.007
30. Kumar P, Thankar MS, Ouyang W, Malarkannan S. IL-22 from
conventional NK cells is epithelial regenerative and inflammation
protective during influenza infection. Mucosal Immunol. (2013) 6:69–82.
doi: 10.3109/02656736.2015.1007538.Histotripsy
31. Guo H, Topham DJ. Interleukin-22 (IL-22) production by pulmonary
natural killer cells and the potential role of IL-22 during primary influenza
virus infection. J. Virol. (2010) 84:7750–9. doi: 10.1128/JVI.00187-10
32. VanMaele L, Carnoy C, Cayet D, Ivanov S, Porte R, Deruy E, et al. Activation
of type 3 innate lymphoid cells and interleukin 22 secretion in the lungs
during Streptococcus pneumoniae infection. J Infect Dis. (2014) 210:493–503.
doi: 10.1093/infdis/jiu106
33. World Health Organization. Pneumonia Fact Sheet (2016). Available online
at: http://www.who.int/news-room/fact-sheets/detail/pneumonia (Accessed
July 30, 2018).
34. Mizgerd JP. Pathogenesis of severe pneumonia - advances
and knowledge gaps. Curr Opin Pulm Med. (2017) 23:193–7.
doi: 10.1097/MCP.0000000000000365
35. Bayes HK, Ritchie ND, Evans TJ. IL-17 is required for control of chronic
lung infection caused by Pseudomonas aeruginosa. Infect Immun. (2016)
84:3507–16. doi: 10.1128/IAI.00717-16
36. Chen K, Eddens T, Trevejo-nunez G, Way EE, Elsegeiny W, Ricks DM, et al.
IL-17 receptor signalling in the lung epithelium is required for mucosal
chemokine gradients and pulmonary defence against K. pneumoniae. Cell
Host Microb. (2017) 20:596–605. doi: 10.1016/j.chom.2016.10.003.IL-17
37. Murakami T, Hatano S, Yamada H, Iwakura Y, Yoshikai Y. Two types
of interleukin 17A-producing γδ T cells in protection against pulmonary
infection with Klebsiella pneumoniae. J Infect Dis. (2016) 214:1752–61.
doi: 10.1093/infdis/jiw443
38. Lévy R, Okada S, Béziat V, Moriya K, Liu C, Chai LYA, et al. Genetic,
immunological, and clinical features of patients with bacterial and fungal
infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci USA.
(2016) 8277–85. doi: 10.1073/pnas.1618300114
39. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger
P, et al. Requirement of interleukin 17 receptor signaling for lung
Frontiers in Immunology | www.frontiersin.org 6 January 2019 | Volume 10 | Article 92
Ardain et al. ILC3s and Lung Disease
Cxc chemokine and granulocyte colony-stimulating factor expression,
neutrophil recruitment, and host defense. J Exp Med. (2001) 194:519–28.
doi: 10.1084/jem.194.4.519
40. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, et al. Interleukin-17A
mediates acquired immunity to pneumococcal colonization. PLoS Pathog.
(2008) 4:e1000159. doi: 10.1371/journal.ppat.1000159
41. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-
dependent clearance of pneumococcal colonization in mice. J Clin Investig.
(2009) 119:1899–909. doi: 10.1172/JCI36731
42. Chen K, McAleer JP, Lin Y, Paterson DL, ZhengM, Alcorn JF, et al. Th17 cells
mediate clade specific, serotype-independent mucosal immunity. Immunity
(2011) 35:997–1009. doi: 10.1016/j.dci.2009.07.003
43. Xiong H, Keith JW, Samilo DW, Carter RA, Leiner IM, Pamer EG. Innate
lymphocte/Ly6Chi monocyte crosstalk promotes Klebsiella pneumoniae
clearance. Cell (2017) 165:679–89. doi: 10.1016/j.cell.2016.03.017.Innate
44. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22
mediates mucosal host defense against Gram-negative bacterial pneumonia.
Nat Med. (2008) 14:275–81. doi: 10.1038/nm1710
45. Broquet A, Jacqueline C, Davieau M, Besbes A, Roquilly A, Martin J, et al.
Interleukin-22 level is negatively correlated with neutrophil recruitment in
the lungs in a Pseudomonas aeruginosa pneumonia model. Sci Rep. (2017)
7:1–11. doi: 10.1038/s41598-017-11518-0
46. Gray J, Oehrle K, Worthen G, Alenghat T, Whitsett J, Deshmukh H.
Intestinal commensal bacteria mediate lung mucosal immunity and promote
resistance of newborn mice to infection. Sci Transl Med. (2017) 9:eaaf9412.
doi: 10.1126/scitranslmed.aaf9412
47. WHO. Global Tuberculosis Report 2016. Cdc 2016, (Global TB Report 2016)
(2016). 214 p.
48. Maertzdorf J, Tonnies M, Lozza L, Schommer-Leitner S, Mollenkopf
H, Bauer TT, Kaufmann SHE. Mycobacterium tuberculosis invasion
of the human lung : first contact. Front Immunol. (2018) 9:1346.
doi: 10.3389/fimmu.2018.01346
49. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR.
The immune response in tuberculosis. Annu Rev Immunol. (2013) 31:475–
527. doi: 10.1146/annurev-immunol-032712-095939
50. Steigler P, Daniels NJ, McCulloch TR, Ryder BM, Sandford SK, Kirman
JR. BCG vaccination drives accumulation and effector function of innate
lymphoid cells in murine lungs. Immunol Cell Biol. (2018) 96:379–89.
doi: 10.1111/imcb.12007
51. McHedlidze T, Waldner M, Zopf S, Walker J, Rankin AL, Schuchmann
M, et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic
fibrosis. Immunity (2013) 39:357–71. doi: 10.1016/j.immuni.2013.07.018
52. Feng CG, Kaviratne M, Rothfuchs AG, Cheever A, Hieny S, Young
HA, et al. NK Cell-Derived IFN- differentially regulates innate
resistance and neutrophil response in T cell-deficient hosts infected
with Mycobacterium tuberculosis. J Immunol. (2006) 177:7086–93.
doi: 10.4049/jimmunol.177.10.7086
53. Cooper BAM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM.
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp
Med. (1993) 178:2243–7.
54. Flynn JAL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ,
et al. Tumor necrosis factor-α is required in the protective immune response
against mycobacterium tuberculosis in mice. Immunity (1995) 2:561–72.
doi: 10.1016/1074-7613(95)90001-2
55. Keane J, Gershon S, Wise RP, Mirable-Levens E, Kasznica J, Schwieterman
WD, et al. Tuberculosis associated with infliximab, a tumor necrosis
factor alpha-neutralizing agent. NEngl J Med. (2001) 345:1098–104.
doi: 10.2165/00128415-200108740-00003
56. Yoshida YO, Umemura M, Brien RLO, Ikuta K, Kishihara K. Essential role
of IL-17A in the formation of a mycobacterial infection-induced granuloma
in the lung. J Immunol. (2010) 184:4414–22. doi: 10.4049/jimmunol.0903332
57. Gopal R, Monin L, Slight S, Uche U, Blanchard E, Fallert Junecko
BA, et al. Unexpected role for IL-17 in protective immunity against
hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog.
(2014) 10:e1004099. doi: 10.1371/journal.ppat.1004099
58. Treerat P, Prince O, Cruz-Lagunas A, Munoz-Torrico M, Salazar-Lezama
MA, Selman M, et al. Novel role for IL-22 in protection during chronic
Mycobacterium tuberculosis HN878 infection. Mucosal Immunol. (2017)
10:1069–81. doi: 10.1159/000450855.Gene-environment
59. Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LVM,
et al. IL-22 Produced by human NK cells inhibits growth of Mycobacterium
tuberculosis by enhancing phagolysosomal fusion. J Immunol. (2009)
183:6639–45. doi: 10.4049/jimmunol.0902587
60. Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M,
et al. Impairment of immunity to Candida and Mycobacterium in
humans with bi-allelic RORC mutations. Science (2016) 349:606–13.
doi: 10.1111/acem.12550.Hot
61. Day TA, Koch M, Nouailles G, Jacobsen M, Kosmiadi GA, Miekley D, et al.
Secondary lymphoid organs are dispensable for the development of T-cell-
mediated immunity during tuberculosis. Eur J Immunol. (2010) 40:1663–73.
doi: 10.1002/eji.201040299
62. Slight SR, Rangel-moreno J, Gopal R, Lin Y, Junecko BAF, Mehra S, et al.
CXCR5+ T helper cells mediate protective immunity against tuberculosis. J
Clin Investig. (2013) 123:1–15. doi: 10.1172/JCI65728DS1
63. Ulrichs T, Kosmiadi GA, Trusov V, Jörg S, Pradl L, TitukhinaM, et al. Human
tuberculous granulomas induce peripheral lymphoid follicle-like structures
to orchestrate local host defence in the lung. J Pathol. (2004) 204:217–28.
doi: 10.1002/path.1628
64. Khader SA, Guglani L, Rangel-moreno J, Gopal R, Beth A, Junecko F,
Fountain JJ, et al. IL-23 is required for long-term control of Mycobacterium
tuberculosis and B cell follicle formation in the infected lung. J Immunol.
(2012) 187:5402–7. doi: 10.4049/jimmunol.1101377.IL-23
65. Gopal R, Rangel-Moreno J, Slight S, Lin Y, Nawar HF, Fallert Junecko
BA, et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine–
induced immunity against tuberculosis.Mucosal Immunol. (2013) 6:972–84.
doi: 10.1038/mi.2012.135
66. Rangel-Moreno J, Carragher DM, de la Lu Garcia-Hernandez M, Hwang
Y, Kusser K, Hartson L, et al.. The development of inducible Bronchus-
associated lymphoid tissue (iBALT) is dependent on IL-17. Nat Immunol.
(2012) 12:639–46. doi: 10.1038/ni.2053.The
67. Ciccia F, Accardo-Palumbo A, Alessandro R, Rizzo A, Principe S, Peralta S,
et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer
cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis
Rheum. (2012) 64:1869–78. doi: 10.1002/art.34355
68. Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH,
et al. CD4 + Group 1 Innate Lymphoid Cells (ILC) form a functionally
distinct ILC subset that is increased in systemic sclerosis. J Immunol. (2016)
196:2051–62. doi: 10.4049/jimmunol.1501491
69. Shikhagaie MM, Germar K, Bal SM, Ros XR, Spits H. Innate lymphoid
cells in autoimmunity: emerging regulators in rheumatic diseases. Nat Rev
Rheumatol. (2017) 13:164–73. doi: 10.1038/nrrheum.2016.218
70. Teunissen MBM, Yeremenko NG, Baeten DLP, Chielie S, Spuls PI, De Rie
MA, et al. The IL-17A-producing CD8 + T-cell population in psoriatic
lesional skin comprises mucosa-associated invariant t cells and conventional
t cells. J Investig Dermatol. (2014) 134:2898–907. doi: 10.1038/jid.
2014.261
71. Saha S, Doe C, Mistry V, Siddiqui S, Parker D, Sleeman M, et al.
Granulocyte-macrophage colony-stimulating factor expression in induced
sputum and bronchial mucosa in asthma and COPD. Thorax (2009) 64:671–
6. doi: 10.1136/thx.2008.108290
72. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, et al. IL-
17 is increased in asthmatic airways and induces human bronchial
fibroblasts to produce cytokines. J Allergy Clin Immunol. (2001) 108:430–8.
doi: 10.1067/mai.2001.117929
73. Kim HY, Lee HJ, Chang Y-J, Pichavant M, Shore Sa, Fitzgerald KA,
et al. Interleukin-17-producing innate lymphoid cells and the NLRP3
inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med.
(2014) 20:54–61. doi: 10.1038/nm.3423
74. Hekking PP, Loza MJ, Pavlidis S, de Meulder B, Lefaudeux D, Baribaud
F, et al. Pathway discovery using transcriptomic profiles in adult-
onset severe asthma. J Allergy Clin Immunol. (2018) 141:1280–90.
doi: 10.1016/j.jaci.2017.06.037
75. Everaere L, Ait-Yahia S, Molendi-Coste O, Vorng H, Quemener S, LeVu
P, et al. Innate lymphoid cells contribute to allergic airway disease
Frontiers in Immunology | www.frontiersin.org 7 January 2019 | Volume 10 | Article 92
Ardain et al. ILC3s and Lung Disease
exacerbation by obesity. J Allergy Clin Immunol. (2016) 138:1309–1318.e11.
doi: 10.1016/j.jaci.2016.03.019
76. Schnyder B, Lima C, Schnyder-Candrian S. Interleukin-22 is a
negative regulator of the allergic response. Cytokine (2010) 50:220–7.
doi: 10.1016/j.cyto.2010.02.003
77. Besnard AG, Sabat R, Dumoutier L, Renauld JC, Willart M, Lambrecht
B, et al. Dual role of IL-22 in allergic airway inflammation and its
cross-talk with IL-17A. Am J Respir Crit Care Med. (2011) 183:1153–63.
doi: 10.1164/rccm.201008-1383OC
78. Takahashi K, Hirose K, Kawashima S, Niwa Y,Wakashin H, Iwata A, et al. IL-
22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-
induced eosinophilic airway inflammation. J Allergy Clin Immunol. (2011)
128:1067–1076.e6. doi: 10.1016/j.jaci.2011.06.018
79. Taube C, Tertilt C, Gyülveszi G, Dehzad N, Kreymborg K, Schneeweiss
K, et al. IL-22 is produced by innate lymphoid cells and limits
inflammation in allergic airway disease. PLoS ONE (2011) 6:e21799.
doi: 10.1371/journal.pone.0021799
80. World Health Organization. Global Surveilance, Prevention and Control of
Chronic Respiratory Diseases: A Comprehensive Approach. Geneva: WHO
Press (2007).
81. Stefano ADi, Caramori G, Gnemmi I, Contoli M, Vicari C. T helper type 17
-related cytokine expression is increased in the bronchial mucosa of stable
chronic obstructive pulmonary disease patients. Clin Exp Immunol. (2009)
157:316–24. doi: 10.1111/j.1365-2249.2009.03965.x
82. Silver JS, Kearley J, Copenhaver AM, Sanden C, Mori M, Yu L, et al.
Inflammatory triggers associated with exacerbations of COPD orchestrate
plasticity of group 2 innate lymphoid cells in the lungs. Nat Immunol. (2016)
17:626–35. doi: 10.1038/ni.3443
83. Lindén A, Hoshino H, Laan M. Airway neutrophils and interleukin-17. Eur
Respir J. (2000) 15:973–7. doi: 10.1034/j.1399-3003.2000.15e28.x
84. Blomme E, Provoost S, Bracke KR, Joos GF, Brusselle GG, Maes T.
Quantification of innate lymphoid cell subsets in a mouse model of
chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
(2018) 197:A4757. Available online at: https://www.atsjournals.org/doi/abs/
10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A4757
85. Doe C, Bafadhel M, Siddiqui S, Mccormick M, Woods J, May R. Expression
of the T Helper 17-associated cytokines IL-17A and IL-17F in asthma. Chest
(2010) 138:1140–7. doi: 10.1378/chest.09-3058
86. Suzuki M, Sze MA, Campbell JD, Brothers JF, Lenburg ME,
McDonough JE, et al. The cellular and molecular determinants
of emphysematous destruction in COPD. Sci Rep. (2017) 7:9562.
doi: 10.1038/s41598-017-10126-2
87. Zhang Y, Tang J, Tian Z, van Velkinburgh JC, Song J, Wu Y,
et al. Innate lymphoid cells: a promising new regulator in fibrotic
diseases. Int Rev Immunol. (2016) 35:399–414. doi: 10.3109/08830185.2015.
1068304
88. Richards CD. Innate immune cytokines, fibroblast phenotypes, and
regulation of extracellular matrix in lung. J Interferon Cytok Res. (2017)
37:52–61. doi: 10.1089/jir.2016.0112
89. Kehlen A, Pachnio A, Thiele K, Langner J. Gene expression induced by
interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid
arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res
Ther. (2003) 5:R186–92. doi: 10.1186/ar762
90. Saleh A, Shan L, Halayko AJ, Kung S, Gounni AS. Critical role for STAT3 in
IL-17A-mediated CCL11 expression in human airway smooth muscle cells. J
Immunol. (2009) 182:3357–65. doi: 10.4049/jimmunol.0801882
91. Brodlie M, McKean MC, Johnson GE, Anderson AE, Hilkens CMU,
Fisher AJ, et al. Raised interleukin-17 is immunolocalised to neutrophils
in cystic fibrosis lung disease. Eur Respir J. (2011) 37:1378–85.
doi: 10.1183/09031936.00067110
92. Wilson MS, Madala SK, Ramalingam TR, Gochuico R, Rosas IO, Cheever
AW, et al. Bleomycin and IL-1B – mediated pulmonary fibrosis is IL-17A
dependent. J Exp Med. (2006) 207:535–52. doi: 10.1084/jem.20092121
93. Lo Re S, Dumoutier L, Couillin I, Van Vyve C, Yakoub Y, Uwambayinema F,
et al. IL-17A-Producing T and Th17 lymphocytes mediate lung inflammation
but not fibrosis in experimental silicosis. J Immunol. (2010) 184:6367–77.
doi: 10.4049/jimmunol.0900459
94. Simonian PL, Wehrmann F, Roark CL, Born WK, O’Brien RL, Fontenot
AP. γδ T cells protect against lung fibrosis via IL-22. J Exp Med. (2010)
207:2239–53. doi: 10.1084/jem.20100061
95. Liang M, Wang J, Chu H, Zhu X, He H, Liu Q, et al. Interleukin-22
inhibits bleomycin-induced pulmonary fibrosis. Mediat Inflamm. (2013)
2013:209179. doi: 10.1155/2013/209179
96. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser La, Artis D. Pathological
versus protective functions of IL-22 in airway inflammation are regulated by
IL-17A. J Exp Med. (2010) 207:1293–305. doi: 10.1084/jem.20092054
97. Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte
R, et al. NCR(+)ILC3 concentrate in human lung cancer and associate
with intratumoral lymphoid structures. Nat Commun. (2015) 6:8280.
doi: 10.1038/ncomms9280
98. Hagau N, Slavcovici A, Gonganau DN, Oltean S, Dirzu DS, Brezoszki ES,
et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus
infection. Crit Care (2010) 14:R203. doi: 10.1186/cc9324
99. Sendo S, Saegusa J, Okano T, Takahashi S, Akashi K, Morinobu A.
CD11b+Gr-1dim tolerogenic dendritic cell–like cells are expanded in
interstitial lung disease in SKG Mice. Arthritis Rheumatol. (2017) 69:2314–
27. doi: 10.1002/art.40231
100. Tan H, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17
pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med. (2011)
184:252–8. doi: 10.1164/rccm.201102-0236OC
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Ardain, Porterfield, Kløverpris and Leslie. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 8 January 2019 | Volume 10 | Article 92
